Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
One in three Americans are obese. Obese subjects may or may not need higher doses of the
anti-flu drug known as Tamiflu (oseltamivir). The current study is being done to see if the
FDA approved dose of oseltamivir will achieve similar concentrations in obese healthy
volunteers compared to that previously shown in non-obese volunteers.